GSK to sell remaining 4.2% stake in Haleon
GSK said on Thursday that it plans to sell its entire remaining 4.2% stake in Haleon.
FTSE 100
8,215.48
17:14 12/06/24
n/a
n/a
FTSE 350
4,526.69
17:09 12/06/24
n/a
n/a
FTSE All-Share
4,482.40
16:49 12/06/24
n/a
n/a
GSK
1,605.00p
17:14 12/06/24
-0.62%
-10.00p
Haleon
320.80p
17:15 12/06/24
-0.09%
-0.30p
Pharmaceuticals & Biotechnology
23,131.93
17:09 12/06/24
0.34%
79.47
The pharmaceutical company will sell about 385m ordinary shares in consumer health business Haleon, which it spun off in July 2022.
GSK initially retained a 12.9% stake in Haleon, but has since sold stakes in May 2023, October 2023 and January 2024.
The final disposal will be conducted through a placing of ordinary shares to institutional investors. GSK said the offer price will be determined by means of an accelerated bookbuild offering process which will start immediately.